STOCK TITAN

BioXcel Therapeutics: Proposed plan may mean no recovery

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

BioXcel Therapeutics, Inc., now named BX Liquidation, Inc., says it cannot file its Form 10-Q for the quarter ended September 30, 2026 within the Rule 12b-25 extension and does not expect to file that report or any subsequent periodic report.

The company filed voluntary Chapter 11 petitions on August 27, 2026, completed the sale of substantially all its assets on October 26, 2026, and is winding down while seeking approval of a proposed liquidation plan. Its executive officers, including the Chief Financial Officer, were removed and their employment terminated effective October 31, 2026. Remaining personnel are focused on the bankruptcy cases and wind-down; the financial statements and independent accountant’s review remain incomplete.

The company anticipates significant changes in quarterly results from Chapter 11 reorganization items, professional fees, debtor-in-possession financing and the asset sale, but cannot provide a reasonable quantitative estimate. It says trading in the common stock is highly speculative and holders may receive little or no recovery under the proposed plan.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Common-stock holders may receive little or no recovery under the proposed Chapter 11 liquidation plan.

Filing Explained

Nasdaq trading in the common stock was suspended on September 8, 2026, and the shares are currently quoted on OTC Pink as BTAIQ; the November 13, 2026 name change to BX Liquidation has not yet been processed by FINRA or the transfer agent, and Nasdaq has not filed Form 25.

Chapter 11 petitions filed August 27, 2026 The company and its subsidiaries filed voluntary petitions.
Substantially all asset sale completed October 26, 2026 The company completed the sale of substantially all its assets.
Nasdaq trading suspension September 8, 2026 Trading in the company’s common stock was suspended.
Name change effective November 13, 2026 The company changed its name to BX Liquidation, Inc.
chapter 11 regulatory
"voluntary petitions for relief under chapter 11"
Chapter 11 is a U.S. bankruptcy process that lets a financially distressed company keep operating while it reorganizes its debts and business plan under court supervision. Think of it as a formal pause that allows the company to renegotiate payments, shed contracts or assets, and seek a path to profitability instead of being liquidated; investors watch it because it can change the value and priority of claims, equity dilution, or the likelihood of recovery.
Rule 12b-25 regulatory
"extension period provided by Rule 12b-25"
Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.
debtor-in-possession financing financial
"the Company’s debtor-in-possession financing"
Financing provided to a company while it reorganizes under bankruptcy protection that lets it keep operating, pay employees and suppliers, and pursue a restructuring plan. Think of it as a court-approved bridge loan or lifeline that typically gets paid back before older debts, so it can change who gets paid and how much investors or creditors ultimately recover; that makes it a key factor in assessing risk and potential returns.
OTC Pink marketplace technical
"currently quoted on the OTC Pink marketplace"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why is BTAIQ’s September 2026 10-Q late?

The company says its limited remaining personnel and resources are focused on the Chapter 11 cases and wind-down. It could not complete the quarter’s financial statements, including accounting for the bankruptcy cases and asset sale, or allow its independent accountant to complete the review in time.

What does the proposed Chapter 11 plan mean for BTAIQ shareholders?

The company says holders of common stock may receive little or no recovery under its proposed Plan. It also cautions that trading during the Chapter 11 cases is highly speculative and that trading prices may bear little or no relationship to any actual recovery.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

NOTIFICATION OF LATE FILING

 

SEC FILE NUMBER CUSIP NUMBER
   
001-38410 09075P204

 

(Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR

 

For Period Ended: September 30, 2026

 

¨ Transition Report on Form 10-K

¨ Transition Report on Form 20-F

¨ Transition Report on Form 11-K

¨ Transition Report on Form 10-Q

 

For the Transition Period Ended: Not applicable

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Not applicable.

 

PART I — REGISTRANT INFORMATION

 

BX Liquidation, Inc.

Full Name of Registrant

 

BioXcel Therapeutics, Inc.

Former Name if Applicable

 

455 Tarrytown Road, Box #1411

Address of Principal Executive Office (Street and Number)

 

White Plains, NY 10607

City, State and Zip Code

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

¨ (a)         The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
  (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN, or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

BX Liquidation, Inc., formerly known as BioXcel Therapeutics, Inc. (the “Company”), was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Quarterly Report”) by the prescribed due date for the reasons described below.

 

As previously disclosed, on August 27, 2026, the Company and its subsidiaries filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (Case No. 26-11360 (TMH)). On October 26, 2026, the Company completed the sale of substantially all of its assets, and the Company is winding down its affairs and pursuing approval of a proposed chapter 11 plan of liquidation (the “Plan”). Effective November 13, 2026, the Company changed its name from “BioXcel Therapeutics, Inc.” to “BX Liquidation, Inc.”

 

Trading in the Company’s common stock on The Nasdaq Stock Market LLC was suspended on September 8, 2026, and the common stock is currently quoted on the OTC Pink marketplace under the symbol “BTAIQ.” The name change has not yet been processed by FINRA or the Company’s transfer agent. Nasdaq has not yet filed a Form 25 with respect to the common stock.

 

In connection with the sale and the wind-down of the Company’s affairs, effective as of 5:00 p.m., Eastern Time, on October 31, 2026, the Company’s executive officers, including its Chief Financial Officer, were removed from office and their employment with the Company was terminated. The Company’s limited remaining personnel and resources are focused on the administration of the chapter 11 cases and the wind-down of the Company’s affairs. As a result, the Company is unable, without unreasonable effort or expense, to complete the preparation of its financial statements for the quarter ended September 30, 2026, including the accounting for and disclosure of the effects of the chapter 11 cases and the sale, and to permit its independent registered public accounting firm to complete its review of such financial statements, in time to file the Quarterly Report by the prescribed due date.

 

Accordingly, the Company will be unable to file the Quarterly Report within the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and does not expect to file the Quarterly Report or any subsequent periodic report.

 

 

PART IV — OTHER INFORMATION

 

(1)Name and telephone number of person to contact in regard to this notification

 

Samir Saleem   (833)   995-7795
(Name)     (Area Code)     (Telephone Number)  

 

(2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

 

x Yes ¨ No

 

(3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

x Yes ¨ No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

The Company anticipates that its results of operations for the quarter ended September 30, 2026 will reflect significant changes from the quarter ended September 30, 2025, principally as a result of the commencement of the chapter 11 cases on August 27, 2026, including reorganization items and professional fees incurred in connection with the chapter 11 cases, the Company’s debtor-in-possession financing, and the Company’s entry into an asset purchase agreement, dated August 27, 2026, for the sale of substantially all of its assets. For the reasons described in Part III above, the Company’s financial statements for the quarter have not been completed, and the Company is therefore unable to provide a reasonable quantitative estimate of these changes at this time.

 

The Company cautions that trading in the Company’s common stock during the pendency of the chapter 11 cases is highly speculative and poses substantial risks. Trading prices for the Company’s common stock may bear little or no relationship to the actual recovery, if any, by holders of the common stock in the chapter 11 cases. Under the Plan, holders of the Company’s common stock may receive little or no recovery on account of their shares.

 

Forward-Looking Statements

 

This Form 12b-25 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing of the filing of the Quarterly Report, the anticipated changes in the Company’s results of operations, the chapter 11 cases and the wind-down of the Company’s affairs. These statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the risks described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

 

 

BX Liquidation, Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: November 17, 2026 BX Liquidation, Inc.
     
    /s/ Samir Saleem
  By: Samir Saleem
  Title: President, Secretary and Chief Restructuring Officer

 

 

Keep reading